Time to discharge from the PACU (in minutes) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Occurrence of intraoperative awareness Time points of measure after surgery: 2 to 6 hours;12 hours; 1 day; 2 days; 3 days; 14 days; 30 days; or time point was not reported Measurement tools: simple questioning; interviews; or structured questionna... · adults undergoing surgery with general anaesthesia
BIS showed no clear difference in occurrence of intraoperative awareness Time points of measure after… compared with ETAG (low certainty).
1 finding from 1 review
Time to eye opening · adults undergoing surgery with general anaesthesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to orientation · adults undergoing surgery with general anaesthesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to discharge from the PACU (in minutes) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
30‐day mortality* · people admitted to intensive care units
It is very uncertain whether automated monitoring systems changes 30‐day mortality* compared with standard care (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Failed detection of sepsis (as reported by studies) · people admitted to intensive care units
1 finding from 1 review
Quality of life measured at the latest available time point post‐discharge from ICU (preferred measure SF‐36 then EQ‐5D) · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in secondary malignant neoplasms compared with more courses of chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in death compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Fewer showed no clear difference in progression/relapse compared with more courses of chemotherapy (with or without radiotherapy (high certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus extended‐field radiation (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in death compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus involved‐field radiation showed no clear difference in progression/relapse compared with same chemotherapy plus extended‐field radiation (high certainty).
1 finding from 1 review
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus higher‐dose radiation (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early stages)
Chemotherapy plus lower‐dose radiation showed no clear difference in death compared with same chemotherapy plus higher‐dose radiation (high certainty).
1 finding from 1 review